News & Analysis on Clinical Trial Services & Contract Research And Development
A new bipartisan draft bill released by four US senators late last week seeks to establish a lot-level electronic system to track pharmaceutical products and further secure the US supply chain.
The FDA has finalised guidance on the manufacturing of antibiotics in order to prevent cross-contamination of finished pharmaceuticals and APIs with non-penicillin beta-lactam drugs.
Baxter says it is evaluating a number of options at its newly acquired Minnesota facility, though biosimilars will be the main focus.
The cash-strapped FDA is looking to cut corners any way it can, especially if it can hone in on which pharma manufacturing facilities and sites need to be prioritized for inspections.
Third-party manufacturers of biologics are seeing increased demand but more short term contracts, according to Fujifilm.